- ROUNDTABLE: Pharmacy’s future in sync with technology
- Actavis' Lo Loestrin Fe patent upheld
- EXPERT BLOG: Provider status for pharmacists — one way or another
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
NEW YORK — Generic drug maker Lupin is seeking approval for a generic version of a contraceptive made by Warner Chilcott, according to published reports.
Reuters reported that Lupin had applied for approval of a generic version of Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), an oral contraceptive.
The Food and Drug Administration approved Lo Loestrin Fe in October 2010, and it’s covered by patents set to expire in July 2014 and February 2029, according to the FDA. Warner Chilcott expects to file a patent infringement suit against Lupin, according to Reuters.